SavedAdd your journal

Journals / Bozok Tıp Dergisi / 2026 / Cilt: 5 Sayı: 2

Statine Bağlı Rabdomiyoliz: Olgu Sunumu

Tekin Yıldırım
Hüseyin Ede
Zeynep Tuğba Özdemir
Elif Börekçi
Pages
0–0
Publication Date
2015-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Bu yazıda, ciddi klinik sonuçlara yol açabilme potansiyeli nedeniyle, statin ve fibrat türevlerinin birlikte kullanımına dikkat çekmek amacıyla, statine bağlı gelişen bir rabdomiyoliz olgusunu sunduk.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Statinler hipelipidemi tedavisinde sıklıkla kullanılan güvenilir ilaçlardır.
📊
Key Findings & Data:Statine bağlı rabdomiyoliz en çok korkulan ve en çok bahsedilen yan etki olmasına rağmen nadiren görülür.
💡
Conclusion & Impact:Bu yazıda, ciddi klinik sonuçlara yol açabilme potansiyeli nedeniyle, statin ve fibrat türevlerinin birlikte kullanımına dikkat çekmek amacıyla, statine bağlı gelişen bir rabdomiyoliz olgusunu sunduk.
🔬Design:Makale
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Statinler hipelipidemi tedavisinde sıklıkla kullanılan güvenilir ilaçlardır. Statine bağlı rabdomiyoliz en çok korkulan ve en çok bahsedilen yan etki olmasına rağmen nadiren görülür. Bu yazıda, ciddi klinik sonuçlara yol açabilme potansiyeli nedeniyle, statin ve fibrat türevlerinin birlikte kullanımına dikkat çekmek amacıyla, statine bağlı gelişen bir rabdomiyoliz olgusunu sunduk.

🔖

Cite This Article

Yıldırım, T., Ede, H., Özdemir, Z. T., Börekçi, E. (2015). Statine Bağlı Rabdomiyoliz: Olgu Sunumu. Bozok Tıp Dergisi, Cilt: 5 Sayı: 2, 0–0. https://ajindex.com/articles/1377898

References (23)

  1. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005;84(6):377-85.
  2. Haas CE, Magram Y, Mishra A. Rhabdomyolysis and acute renal failure following an ethanol and diphenhidramine overdose. Ann Pharmacother. 2003;37(4):538-42.
  3. Rodrigez ML, Mora C, Navaro JF. Cerivastatin-induced rhabdomyolisis. Ann Intem Med. 2000;132(7):598.
  4. Unal A, Torun E, Sipahioglu MH, Tokgoz B, Kaya MG, Oymak O, et al. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Inter Med. 2008;47(11):1017-9.
  5. Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16(3):352-8.
  6. Ireland JH, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med. 2005;142(11):949-50.
  7. Kursat S, Alici T, Colak HB. A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism. Clin Nephrol. 2005;64(5):391-3.
  8. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-90.
  9. Antos KA, Williams CD, Baker SK, Philiph PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119(5):400-9.
  10. Polderman KH. Acute renal failure and rhabdomyolysis. Int J Artif Organs. 2004;27(12):1030-3.
  11. A. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med. 2002;137(7):617-8.
  12. Sathasivam S, Lecky B. Statin induced myopathy. BMJ. 2008;337:a2286.
  13. Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23(4):317-24.
  14. Flint OP, Masters BA, Gregg RE, Durham SK. HMG CoA reductase inhibitor-induced myotoxicitiy; pravastatin and lovastatin inhibit the geranylgeranylation of low-molecularweight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol. 1997;145(1):99-110.
  15. Gadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol. 1995;27(10):2397-402.
  16. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, et al. The effect of simvastatin treatment on natural antioxidants in low density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 1996;77(10):851-4.
  17. Rosenson RS. Current overview of statin induced myopathy. Am J Med 2004;116(6):408-16.
  18. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; Ameri-can College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke. 2002;33(9):2337-41.
  19. Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother. 2011;45(10):1230-9.
  20. Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstøl K, et al. Safety of a fixed-dose combination of fenofibra-te/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials. Clin Drug Investig. 2012;32(4):281-91.
  21. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(6A):3C-18C.
  22. Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol. 2007;19(1):67-73.
  23. Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol. 2009;65(12):1169-74.